Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Liquid Biopsy Market Size And Revenue Forecast Through 2030

The market for liquid biopsy has experienced a significant expansion recently, projected to increase from $1.46 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.3%. This notable growth during the past period is largely due to the inherent drawbacks of conventional tissue biopsy methods, a

The liquid biopsy market is poised for significant expansion, projected to reach $3.11 billion by 2030, driven by a robust compound annual growth rate (CAGR) of 16.2%. This forthcoming expansion is fueled by several key factors, including the escalating demand for personalized cancer therapies, a greater integration of liquid biopsy into standard cancer detection protocols, its broadened utility in tracking cancer recurrence, augmented expenditure on cancer diagnostics, and heightened understanding and acceptance among both medical professionals and patients. Within this projected timeframe, notable market developments are anticipated, such as the increased embrace of non-surgical cancer diagnostic methods, a heightened focus on leveraging liquid biopsy for the earliest possible identification of cancer, the growing need for continuous monitoring of therapeutic effectiveness, its wider application in tailored cancer treatment strategies, and its growing endorsement as a viable substitute for traditional tissue biopsies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2815&type=smp

Liquid Biopsy Market Growth Drivers: What Factors Are Accelerating Expansion?

Enhanced governmental financial support directed towards improving cancer detection capabilities stands as a principal factor propelling the expansion of the liquid biopsy sector. This heightened public investment in cancer detection advancements stems largely from the escalating worldwide prevalence of cancer, the critical necessity for early identification to optimize therapeutic results, and a concentrated effort to curb medical expenditures through the implementation of pioneering diagnostic methodologies. Such governmental backing facilitates the liquid biopsy market by expediting research and development initiatives, providing crucial support for clinical studies, and encouraging the uptake of sophisticated, minimally invasive diagnostic tools that aid in earlier cancer identification and the formulation of tailored treatment plans. A pertinent example is the £118 million (equivalent to $150.38) earmarked by UK Research and Innovation, as reported in October 2024 on the UK government’s official platform, gov.UK, where £54 million originated from governmental sources and an additional £64 million (or $81.55) was contributed by collaborating entities, underscoring the significant financial impetus provided for advancements in cancer diagnostics.

Liquid Biopsy Market Segment Performance And Strategic Opportunities

The liquid biopsy market covered in this report is segmented –

1) By Product: Assay Kits, Instruments, Services

2) By Clinical Application: Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring

3) By End User: Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers

Subsegments:

1) By Assay Kits: cfDNA Assays, ctDNA Assays, Exosome-based Assays, RNA-based Assays

2) By Instruments: PCR Instruments, Next-Generation Sequencing (NGS) Instruments, Microarray Instruments

3) By Services: Testing Services, Data Analysis Services, Laboratory Services

Liquid Biopsy Market Trends: What Is Shaping Future Industry Growth?

Key players in the liquid biopsy sector are prioritizing the creation of cutting-edge technologies, like extensive circulating tumor DNA (ctDNA) genomic-profiling assays, with the goal of expediting noninvasive cancer characterization, facilitating quicker medical treatment choices, and expanding the availability of precision oncology, particularly in situations where tissue is scarce or inaccessible. These comprehensive ctDNA genomic-profiling assays work by examining fragments of cell-free DNA originating from tumors present in the bloodstream, thereby identifying somatic small variants, alterations in copy number, insertions or deletions, and indicators relevant to immuno-oncology such as bTMB and bMSI. This approach provides a more extensive understanding of the tumor without the drawbacks of invasive procedures, potential sampling biases, and extended processing times associated with conventional tissue biopsies. Illustrating this, in November 2023, Illumina Inc., a prominent American company specializing in sequencing and genomics, introduced TruSight Oncology 500 ctDNA v2. This research-oriented liquid biopsy panel is designed for the noninvasive genomic assessment of solid tumors and features an enhanced hybrid-capture panel coupled with DRAGEN bioinformatics, enabling the analysis of 523 biomarkers even with minimal cell-free DNA input. The assay adeptly enriches and identifies structural variants, copy number variations, insertions/deletions, and immuno-oncology parameters with impressive analytical precision, offers simplified laboratory processes through a single hybridization step with a turnaround time of less than four days, and is compatible with NovaSeq systems and future automated platforms. It proves beneficial when tissue is not available or its testing is delayed, serves as a valuable supplement to tissue-based testing, and supports extensive pan-cancer research and clinical trial screening by delivering prompt insights, demonstrating efficacy with low-input samples, and facilitating widespread implementation across various laboratory settings.

Liquid Biopsy Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

Access The Complete Liquid Biopsy Market Report:

https://www.thebusinessresearchcompany.com/report/liquid-biopsy-global-market-report

Liquid Biopsy Market Regional Analysis And Leading Geography

North Americawas the largest region in the liquid biopsy market in 2025. Western Europewas the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model